OssDsign (OM:OSSD) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

OSSD Overzicht aandelen

OSSD fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 23.91% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 87.4% zal stijgen

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( SEK643M )

OssDsign AB (publ) Concurrenten

Bactiguard Holding

OM:BACTI B

SEK 1.8b

Invent Medic Sweden

NGM:IMS

SEK 32.9m

Xvivo Perfusion

OM:XVIVO

SEK 15.7b

Senzime

OM:SEZI

SEK 757.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor OssDsign
Historische aandelenkoersen
Huidige aandelenkoers	SEK 6.58
52 Week Hoogtepunt	SEK 10.94
52 Week Laag	SEK 5.58
Bèta	0.82
11 maand verandering	-5.87%
3 maanden verandering	-28.86%
1 Jaar Verandering	7.17%
33 jaar verandering	-24.37%
5 jaar verandering	-65.37%
Verandering sinds IPO	-71.39%

Recent nieuws en updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 23

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

Aug 06

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 23

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

Aug 06

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

Mar 19

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Aug 19

Rendement voor aandeelhouders

	OSSD	SE Medical Equipment	SE Markt
7D	-1.8%	-0.6%	0.8%
1Y	7.2%	21.2%	25.1%

Rendement versus industrie: OSSD presteerde slechter dan de Swedish Medical Equipment -sector, die het afgelopen jaar een rendement van 21.2 % opleverde.

Rendement versus markt: OSSD presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 25.1 % opleverde.

Prijsvolatiliteit

Is OSSD's price volatile compared to industry and market?
OSSD volatility
OSSD Average Weekly Movement	5.1%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.6%
10% least volatile stocks in SE Market	3.2%

Stabiele aandelenkoers: OSSD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van OSSD is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	27	Morten Henneveld	www.ossdsign.com

OssDsign AB (publ) ontwerpt, produceert en verkoopt implantaten en materiaaltechnologie voor botregeneratie in Zweden, Duitsland, de Verenigde Staten, het Verenigd Koninkrijk, de rest van Europa en internationaal. Het bedrijf biedt OssDsign Catalyst aan, een nanosynthetisch bottransplantaat dat wordt gebruikt om de botgroei te stimuleren bij ruggengraatfusies. Het bedrijf is opgericht in 2011 en het hoofdkantoor is gevestigd in Uppsala, Zweden.

OssDsign AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van OssDsign zich tot de beurswaarde?
OSSD fundamentele statistieken
Marktkapitalisatie	SEK 642.60m
Inkomsten(TTM)	-SEK 113.80m
Inkomsten(TTM)	SEK 123.46m

5.2x

P/S-verhouding

-5.6x

Koers/Winstverhouding

Is OSSD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
OSSD resultatenrekening (TTM)
Inkomsten	SEK 123.46m
Kosten van inkomsten	SEK 19.83m
Brutowinst	SEK 103.63m
Overige uitgaven	SEK 217.44m
Inkomsten	-SEK 113.80m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 05, 2024

Winst per aandeel (EPS)	-1.17
Brutomarge	83.94%
Nettowinstmarge	-92.18%
Schuld/Eigen Vermogen Verhouding	0.2%

Hoe presteerde OSSD op de lange termijn?

Bekijk historische prestaties en vergelijking

OSSD Overzicht aandelen

Beloningen

Risicoanalyse

OssDsign AB (publ) Concurrenten

OM:BACTI B

SEK 1.8b

NGM:IMS

SEK 32.9m

OM:XVIVO

SEK 15.7b

OM:SEZI

SEK 757.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 30%, revenue upgraded

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Consensus EPS estimates fall by 15%

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to kr14.00

Insufficient new directors

Consensus revenue estimates fall by 16%

Chief Executive Officer recently bought kr133k worth of stock

Chief Executive Officer recently bought kr133k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Chief Executive Officer recently bought kr124k worth of stock